Portal de Periódicos da CAPES

Inhaled sedation in the intensive care unit

2022; Elsevier BV; Volume: 41; Issue: 5 Linguagem: Inglês

10.1016/j.accpm.2022.101133

2352-5568

Matthieu Jabaudon, Ruoyang Zhai, Raïko Blondonnet, Woodys Lenga Ma Bonda,

Anesthesia and Neurotoxicity Research

Inhaled sedation with halogenated agents, such as isoflurane or sevoflurane, is now feasible in intensive care unit (ICU) patients through dedicated vaporisers and scavenging systems. Such a sedation strategy requires specific equipment and adequate training of ICU teams. Isoflurane and sevoflurane have ideal pharmacological properties that allow efficient, well-tolerated, and titratable light-to-deep sedation. In addition to their function as sedative agents, these molecules may have clinical benefits that could be especially relevant to ICU patients. Our goal was to summarise the pharmacological basis and practical aspects of inhaled ICU sedation, review the available evidence supporting inhaled sedation as a viable alternative to intravenous sedation, and discuss the remaining areas of uncertainty and future perspectives of development.